Usher Syndrome Type 4 (USH4): Comprehensive Research Report

1. Disease Information

Overview

Usher syndrome type IV (USH4) is a rare, autosomal recessive, atypical form of Usher syndrome characterized by late-onset retinitis pigmentosa (RP) with a distinctive pericentral/macular pattern and late-onset, progressive sensorineural hearing loss (SNHL) occurring without vestibular dysfunction. It is caused by biallelic pathogenic variants in ARSG (arylsulfatase G), a lysosomal sulfatase gene, and was only formally delineated as a distinct Usher subtype in 2018 — decades after Usher types I–III were characterized (Khateb et al. 2018, PMID:29300381; OMIM #618144).

USH4 is clinically distinguished from USH1–3 chiefly by the markedly later onset of both sensory deficits (visual symptoms typically in the 3rd–6th decade rather than childhood) and by the complete absence of vestibular involvement, which sets it apart even from USH2 and USH3 in most reported cases (Peter et al. 2022, PMID:35226187).

Key Identifiers

Synonyms / Alternative Names

• USH4
• Atypical Usher syndrome (the term used in the original 2018 report before "type IV" nomenclature was adopted)
• ARSG-related Usher syndrome / ARSG-associated retinitis pigmentosa and hearing loss
• Late-onset Usher syndrome (informal)

Nature of Evidence Base

Nearly all available data derive from aggregated case series and case reports (individual patients and families identified through next-generation sequencing in RP/hearing-loss diagnostic cohorts), not large-scale EHR or population-registry data. As of the most recent (2024/2025) cohort expansion, the total published dataset comprises only 31 molecularly confirmed individuals worldwide (Bauwens et al. 2025, PMID:39199020, Clinical Genetics), making USH4 one of the rarest and most recently characterized Usher subtypes. Supporting mechanistic evidence comes from a mouse knockout model and naturally occurring canine disease.

2. Etiology

Disease Causal Factors

USH4 is caused exclusively by biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic pathogenic variants in ARSG, which encodes the lysosomal sulfatase arylsulfatase G. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause — this is a monogenic Mendelian disorder.

Genetic Risk Factors

• Causal gene: ARSG (HGNC:24145), chromosome 17q24.2. Pathogenic variants abolish or severely reduce sulfatase enzymatic activity.
• Variant spectrum (as of the 2024/2025 cohort of 31 patients across at least 7 publications):
• Missense: p.(Asp45Tyr) [founder, Yemenite Jewish], p.(Asp44Asn), p.(Leu92Pro), p.(Arg99His), p.(Pro213Leu), p.(Arg342Trp), p.(Arg384Trp)
• Nonsense: p.(Tyr196*)
• Frameshift: p.(Thr31Glnfs*9), p.(Gly329Glufs*35), p.(Ser443Alafs*12)
• Splice-site: c.1212+1G>A → p.(Val405Ilefs*41); c.1303+5G>T
• Large deletions: c.705-3940_982+2952del → p.(Ser235Argfs*29); c.219_454del → p.(Val75*)
• (Sources: Khateb 2018; Abad-Morales et al. 2020, PMID:32455177; Peter et al. 2022, PMID:35226187; Bauwens et al. 2025, PMID:39199020)
• Founder variants:
• p.(Asp45Tyr), homozygous in 5 individuals from 3 Yemenite Jewish families in the original description (Khateb et al. 2018).
• c.1150C>T, p.(Arg384Trp) — recurring in 4 of 31 subjects, predominantly of Portuguese origin, suggesting a Portuguese founder allele (Bauwens et al. 2025, PMID:39199020).
• Consanguinity: Reported in multiple families, including a Tunisian consanguineous family and the original Yemenite Jewish kindreds — consistent with the very rare, recessive nature of the disease.
• No modifier genes or digenic contributions have yet been reported for USH4; unlike some USH2A cases, no oligogenic modulation has been documented.

Environmental Risk Factors

None specifically established for USH4. As with other forms of RP, general age-related and noise-exposure factors that affect hearing broadly could theoretically modulate SNHL severity/progression, but no ARSG-specific gene-environment data exist.

Protective Factors

None reported specific to ARSG or USH4. No protective alleles or environmental protective exposures have been documented in the literature to date.

Gene-Environment Interactions

Not studied for USH4 specifically; the extreme rarity of the condition (n=31 published cases) has precluded epidemiological gene-environment analyses.

3. Phenotypes

USH4 phenotypes fall into two principal domains — retinal and auditory — with vestibular function preserved.

Retinal / Ophthalmologic Phenotypes

Age of onset: Visual symptoms (typically night blindness) reported from 18–65 years, with mean onset in the 4th decade (~40s); one outlier case with symptom onset at age 25 (Bauwens et al. 2025). RP onset overall spans 30–60 years across the combined literature (Peter et al. 2022).

Progression: Progressive; leads to combined ERG extinction (both scotopic and photopic responses eventually absent) and complete loss of outer retinal layers in advanced disease.

Auditory Phenotypes

Note the striking discrepancy between "calculated" (regression-based) onset age (~17 years) in the Peter et al. cohort versus the later, more typical clinical onset (40s–50s) in the larger Bauwens et al. cohort — reflecting genuine phenotypic heterogeneity and possibly ascertainment/methodology differences between studies.

Vestibular Phenotype

No vestibular involvement reported in the great majority of patients — this is a defining diagnostic feature distinguishing USH4 from USH1–3. One patient in the Bauwens cohort showed incidental "mild cerebral and cerebellar atrophy" on neuroimaging, but no patient has reported clinical vestibular symptoms (vertigo, balance dysfunction, delayed motor milestones). Suggested term: absence of HP:0000501 (Vestibular dysfunction) — i.e., this is a negative finding of diagnostic significance.

Quality of Life Impact

Not formally studied with validated instruments (EQ-5D, SF-36) specific to USH4 in the literature reviewed. By analogy to Usher syndrome broadly, combined progressive dual-sensory (hearing + vision) loss is expected to substantially affect independence, communication, and mobility, though the later onset in USH4 (relative to USH1) may allow patients a longer period of unaffected functioning before intervention becomes necessary.

4. Genetic/Molecular Information

Causal Gene

• ARSG (Arylsulfatase G), HGNC gene symbol ARSG, chromosome 17q24.2, OMIM *610008.
• Encodes a member of the sulfatase family of lysosomal enzymes.

Variant Classification (ACMG/AMP)

Across the reviewed publications, pathogenicity was established via ACMG/AMP criteria plus functional enzymatic assays: - Missense variants p.(Pro213Leu), p.(Arg384Trp), and p.(Arg99His) were functionally tested and showed "complete loss of sulfatase enzymatic activity" without loss of protein stability (Bauwens et al. 2025, PMID:39199020). - The original founder variant p.(Asp45Tyr) was shown to abolish enzymatic activity in the paper's title itself: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans" (Khateb et al. 2018, PMID:29300381). - Missense pathogenic variants also impede correct lysosomal localization, with mutant protein retained aberrantly in the endoplasmic reticulum rather than trafficking to the lysosome.

Variant Type/Class Distribution

Mixed allelic series including missense, nonsense, frameshift, canonical splice-site, and large intragenic deletions — no single dominant mutational mechanism, consistent with a classic loss-of-function recessive disease gene.

Allele Frequency

Individual ARSG pathogenic variants are extremely rare/private in population databases (gnomAD), consistent with the extreme rarity of the phenotype (only 31 published cases worldwide); the two founder alleles (Yemenite Jewish p.Asp45Tyr; presumptive Portuguese p.Arg384Trp) are expected to show population-specific enrichment but specific gnomAD allele counts were not available from the sources reviewed here and should be verified directly in gnomAD/ClinVar before curation.

Somatic vs. Germline

Exclusively germline — USH4 is a classic Mendelian recessive disorder with no somatic/mosaic mechanism reported.

Functional Consequences

Loss of function — pathogenic ARSG variants abolish sulfatase catalytic activity and, for at least some missense alleles, cause ER retention/mistrafficking rather than proper lysosomal delivery, representing a combined catalytic-loss + trafficking-defect mechanism.

Modifier Genes

None reported.

Epigenetic Information

No epigenetic (DNA methylation, histone) data specific to ARSG/USH4 were identified in the literature reviewed.

Chromosomal Abnormalities

No aneuploidy, translocation, or large structural chromosomal rearrangements reported as a cause of USH4; the largest documented lesion is an intragenic multi-exon deletion (c.705-3940_982+2952del).

5. Environmental Information

No environmental, occupational, lifestyle, or infectious causal/risk factors have been documented for USH4 specifically in the literature. As a purely monogenic recessive disorder, environmental contribution to primary disease causation is not established. (General environmental modifiers of hearing loss and RP progression that apply across all forms of these sensory disorders — e.g., noise exposure, UV exposure — have not been specifically studied in the ARSG-USH4 context.)

6. Mechanism / Pathophysiology

Molecular Function of ARSG

ARSG encodes a lysosomal sulfatase ("arylsulfatase G") that functions in the stepwise lysosomal degradation of heparan sulfate, specifically removing terminal N-sulfoglucosamine-3-O-sulfate residues from the non-reducing end of heparan sulfate chains (OMIM *610008; GeneCards ARSG summary).

Tissue/Cellular Localization

In the mouse retina, ARSG protein expression is restricted to the retinal pigment epithelium (RPE) — it is not detectably expressed in photoreceptors themselves. Heparan sulfate proteoglycans are components of the interphotoreceptor matrix that must be turned over by RPE lysosomal machinery (Kruszewski et al. 2016, IOVS, PMID:26975023).

Proposed Causal Chain (Retina)

1. Trigger: Biallelic ARSG loss-of-function variants → loss of arylsulfatase G catalytic activity in RPE lysosomes.
2. Molecular consequence: Failure to degrade terminal sulfated heparan sulfate residues → accumulation of undegraded heparan sulfate proteoglycans within RPE phagolysosomes.
3. Secondary consequence: Because RPE lysosomes also process phagocytosed photoreceptor outer-segment material daily, storage-material accumulation is proposed to secondarily impair RPE handling of photoreceptor outer segment components, including recycling/delivery of the visual chromophore 11-cis-retinal back to photoreceptors — a function essential for the visual (retinoid) cycle.
4. Cellular consequence: Impaired RPE support function → progressive photoreceptor cell death, with reactive astrogliosis and microgliosis (evident in outer but not inner retina) as downstream inflammatory/reactive changes, and elevated expression of other lysosomal proteins as a compensatory/stress response (Kruszewski et al. 2016, PMID:26975023).
5. Clinical consequence: Progressive rod-cone dystrophy with the ring/pericentral atrophy pattern characteristic of USH4.

This is mechanistically analogous to other lysosomal storage disease paradigms (heparan sulfate is also the accumulating substrate in Mucopolysaccharidosis III/Sanfilippo syndrome, which is caused by defects in other heparan-sulfate-degrading sulfatases/enzymes), positioning USH4 within the broader lysosomal substrate-accumulation disease-mechanism class.

Mechanism in the Cochlea

The precise cochlear cell-autonomous mechanism of ARSG-related hearing loss is less well characterized experimentally than the retinal mechanism, but by analogy is presumed to involve heparan sulfate proteoglycan accumulation in inner-ear supporting/epithelial cells impairing normal cochlear homeostasis and hair-cell/spiral-ganglion function, producing progressive high-frequency sensorineural hearing loss.

Cell Types Involved

• Retinal pigment epithelial cell (site of primary ARSG deficiency) — suggested CL term: CL:0002586 (retinal pigment epithelial cell)
• Photoreceptor cell (rod and cone; site of secondary degeneration) — CL:0000210 (photoreceptor cell); CL:0000604 (retinal rod cell); CL:0000573 (retinal cone cell)
• Cochlear hair cells / spiral ganglion neurons (presumed site of auditory pathology, not directly demonstrated) — CL:0000601 (auditory hair cell); CL:0000392 (spiral ganglion neuron, if applicable)
• Astrocytes and microglia (reactive gliosis in the outer retina) — CL:0000127 (astrocyte); CL:0000129 (microglial cell)

Suggested GO Terms

• GO:0008484 (sulfuric ester hydrolase activity) — molecular function of ARSG
• GO:0030201 (heparan sulfate proteoglycan metabolic process)
• GO:0030203 (glycosaminoglycan metabolic process)
• GO:0007601 (visual perception)
• GO:0016185 (synaptic vesicle within endosome — not directly relevant)
• GO:0034381 (plasma lipoprotein particle clearance — not relevant)
• GO:0007605 (sensory perception of sound)
• GO:0034976 (response to endoplasmic reticulum stress) — relevant given ER-retention mechanism of some missense alleles

Molecular Profiling / Omics

No transcriptomic, proteomic, or single-cell datasets specific to human USH4/ARSG-deficient tissue were identified in the literature search. The mouse knockout model (below) provides tissue-level histopathology but not published omics datasets in the sources reviewed.

7. Anatomical Structures Affected

Organ Level

• Primary organs: Eye (retina) and ear (cochlea/inner ear)
• Body systems: Visual system and auditory system; no vestibular system involvement (a key negative finding); no other organ systems are affected in isolated USH4 (unlike the canine ARSG phenotype, which involves broader CNS/cerebellar disease — see Section 14).
• Suggested UBERON terms: UBERON:0000966 (retina), UBERON:0001690 (ear), UBERON:0002104 (retinal pigment epithelium), UBERON:0001846 (organ of Corti — cochlear structure)

Tissue and Cell Level

• Retinal pigment epithelium — primary site of ARSG expression and enzymatic deficiency.
• Neural retina (photoreceptor layer, particularly outer segments) — site of secondary degeneration.
• Cochlear sensory epithelium — presumed site of auditory pathology (not directly demonstrated histologically in humans).

Subcellular Level

• Lysosome — the organelle where ARSG normally functions and where undegraded substrate accumulates (GO Cellular Component: GO:0005764, lysosome; GO:0005775, vacuolar lumen).
• Endoplasmic reticulum — site of aberrant retention of mistrafficked mutant ARSG protein for at least some missense alleles (GO:0005783, endoplasmic reticulum).

Localization

• Retina: Ring-shaped/pericentral pattern of atrophy around the vascular arcades and macula, with relative sparing of mid- and far-periphery — a distinctive localization pattern that differentiates USH4 from the more diffuse peripheral-to-central RP typical of USH1/2.
• Ear: Bilateral hearing loss (no reported unilateral/asymmetric cases); no vestibular (semicircular canal/otolith) involvement.

8. Temporal Development

Onset

• Visual (RP) onset: 18–65 years, mean ~40s; markedly later than USH1 (congenital-severe), USH2 (congenital-moderate hearing loss, RP onset childhood/adolescence), and USH3 (progressive childhood-onset hearing loss).
• Auditory onset: Variably reported 40–58 years in the larger recent cohort, though earlier studies calculated an audiometric onset around age 17 based on regression modeling; clinical recognition (hearing aid fitting) more typically occurs ages 18–67.
• Pattern: Insidious, gradual onset for both modalities — not acute or episodic.

Progression

• Retinal: Progressive rod-cone degeneration; combined scotopic/photopic ERG dysfunction progressing over years to complete extinguishment; progressive loss of outer retinal layers on OCT; eventual severe visual field constriction.
• Auditory: Progressive SNHL, estimated at ~1.0–1.5 dB HL/year based on audiometric modeling in one study.
• Course: Chronic, progressive, non-remitting; no episodic or relapsing-remitting pattern reported.
• Duration: Lifelong, chronic condition with no spontaneous remission.

Patterns

• No remission patterns reported (progressive disorder).
• Critical/intervention windows are not formally defined for USH4 but, by analogy to RP generally, earlier diagnosis enables earlier low-vision/hearing rehabilitation and genetic counseling before profound sensory loss develops.

9. Inheritance and Population

Epidemiology

• USH4 is exceptionally rare: only 31 molecularly confirmed patients have been published as of the most recent (2024/2025) cohort expansion (Bauwens et al. 2025, PMID:39199020), up from an initial report of 5 patients in 2018 and small subsequent case series/reports.
• For comparison, Usher syndrome overall has an estimated prevalence of ~1/10,000 (Delmaghani & El-Amraoui 2022, PMID:35353227) to 4–17 per 100,000 people; USH4 represents a very small fraction of this total, reflecting either genuine rarity or under-ascertainment (given its late onset, USH4 patients may be diagnosed as isolated late-onset RP or presbycusis-like hearing loss rather than recognized as syndromic Usher disease).
• No formal incidence, birth-prevalence, or carrier-frequency estimates specific to ARSG/USH4 were identified.

Inheritance Pattern

• Autosomal recessive — all reported cases are homozygous or compound heterozygous for ARSG pathogenic variants.
• Penetrance: Appears complete among biallelic carriers reported to date, though ascertainment bias (patients identified through symptomatic diagnostic sequencing) limits confidence in this conclusion.
• Expressivity: Variable — age of onset for both hearing loss and RP varies substantially between patients (visual onset 18–65 years; hearing loss onset childhood–50s by self-report), and phenotype severity (e.g., presence/absence of cystoid macular edema, degree of hearing loss) also varies.
• Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not specifically reported.
• Founder effects: Documented — Yemenite Jewish founder variant p.(Asp45Tyr); likely Portuguese founder variant p.(Arg384Trp).
• Consanguinity: Reported in several of the founding/index families (Yemenite Jewish kindreds, a Tunisian family).
• Carrier frequency: Not established in the literature reviewed; would require dedicated population screening or gnomAD analysis of specific ARSG alleles.

Population Demographics

• Affected populations: Cases reported from Israel (Yemenite Jewish), Spain, Belgium, France, Portugal, USA, and Tunisia — a geographically and ethnically diverse but numerically very small set of families.
• Geographic distribution: Portugal appears disproportionately represented (9 of 31 total published subjects, including a likely founder allele), suggesting a possible regional enrichment, though this could also reflect ascertainment bias from strong Portuguese ophthalmogenetics research programs.
• Sex ratio: Not specifically reported as skewed; consistent with autosomal (not X-linked) recessive inheritance, no sex predilection is expected.
• Age distribution: All published cases are adults (given the late-onset nature of the disease by definition); no pediatric-onset cases have been reported.

10. Diagnostics

Clinical Tests

• Fundus examination: Ring-shaped/pericentral retinal atrophy pattern around the vascular arcades, extending nasally beyond the optic disc; intraretinal bone-spicule pigmentation predominantly nasal and superior to the disc.
• Optical coherence tomography (OCT): Progressive loss of outer retinal layers, variably with cystoid macular edema.
• Fundus autofluorescence (FAF): Ring-shaped hyperautofluorescence with hypoautofluorescence in the mid-periphery.
• Full-field electroretinogram (ERG): Combined scotopic and photopic dysfunction, progressing to extinguished responses in advanced disease.
• Visual field testing: Ring scotoma (10–20°).
• Pure-tone audiometry: Bilateral, predominantly mid-to-high-frequency, down-sloping sensorineural hearing loss.
• Vestibular testing: Performed to document the absence of vestibular dysfunction, a key differentiating feature from USH1–3 — important for the differential diagnostic workup.

Genetic Testing

• Recommended approach: Given the phenotypic overlap with non-syndromic late-onset RP and with age-related hearing loss, molecular diagnosis of USH4 typically occurs via targeted RP/inherited retinal disease gene panels or hearing-loss gene panels that include ARSG, or via whole-exome sequencing (WES) in cases where syndromic Usher disease is suspected but standard USH1/2/3 gene panels (MYO7A, USH2A, CDH23, PCDH15, CLRN1, etc.) are negative.
• Confirmatory functional testing: Given the relatively recent characterization of ARSG as a disease gene and the predominance of novel/private missense variants (many classified only as "likely pathogenic" on ACMG criteria alone), enzymatic sulfatase activity assays have been used in multiple studies to confirm variant pathogenicity — an important diagnostic adjunct beyond standard variant classification.
• Chromosomal microarray / karyotyping: Not indicated — no reported CNV or chromosomal mechanism beyond the single reported large intragenic deletion.

Clinical Diagnostic Criteria

Proposed diagnostic criteria for USH4 based on Peter et al. 2022 (PMID:35226187): | Feature | USH4 characteristic | |---|---| | Hearing loss | Moderate-to-severe SNHL, later onset than USH1-3 | | Visual impairment | RP onset 30–65 years; pericentral/macular ring-atrophy pattern | | Vestibular function | Normal (no reported dysfunction) | | Genetic basis | Biallelic ARSG variants with loss of sulfatase activity |

Differential Diagnosis

• Non-syndromic autosomal recessive RP (without hearing loss)
• Usher syndrome types 1–3 (distinguished by earlier onset, presence/degree of vestibular dysfunction, and different causal genes: MYO7A/USH1C/CDH23/PCDH15/USH1G for USH1; USH2A/ADGRV1/WHRN for USH2; CLRN1 for USH3)
• Age-related macular degeneration and presbycusis (when onset is very late and family history is not apparent — a plausible source of underdiagnosis)
• Other syndromic retinal-hearing disorders (e.g., Alström syndrome, though this carries additional systemic features)

Screening

No population-based newborn or carrier screening programs specific to ARSG/USH4 exist, consistent with its extreme rarity and late age of onset (which makes newborn screening for this specific indication low-yield).

11. Outcome/Prognosis

Survival and Mortality

USH4 is not associated with reduced life expectancy or increased mortality — it is a purely sensory (visual + auditory), non-life-threatening disorder. No survival/mortality data specific to USH4 were identified (or would be expected) in the literature, consistent with this being a quality-of-life/functional disorder rather than a lethal one.

Morbidity and Function

• Progressive dual sensory impairment, ultimately combining significant visual field constriction/central vision loss with moderate-to-severe hearing loss.
• Because onset is later in life than other Usher types, patients typically have a substantial period of normal or near-normal sensory function before disease manifests, which may lessen the developmental/educational impact seen in congenital forms (USH1) but still poses major challenges to independence, driving, and communication in mid-to-late adulthood.
• No formal quality-of-life instrument data (EQ-5D, SF-36) specific to USH4 were found.

Disease Course

• Complications: Progressive visual field constriction to legal blindness is expected in advanced RP (by analogy with other RP-causing genes); cystoid macular edema, when present, can cause additional acute-on-chronic visual decline.
• Recovery potential: None — as a progressive degenerative disorder, spontaneous recovery is not expected; symptomatic/supportive management (below) aims to slow progression and support residual function rather than reverse disease.

Prognostic Factors

• Specific genotype-phenotype correlations remain incompletely established given the small cohort size, though functionally "null" variants (nonsense, frameshift, large deletions) might be expected to correlate with earlier/more severe disease compared with hypomorphic missense alleles — this has not been rigorously demonstrated in the literature reviewed and should be treated as a hypothesis rather than an established finding.
• No validated prognostic biomarkers specific to ARSG/USH4 have been reported.

12. Treatment

There is no disease-specific, FDA-approved, or ARSG-targeted therapy for USH4. Management is supportive/symptomatic, following the general Usher syndrome treatment paradigm:

Pharmacotherapy

• High-dose vitamin A palmitate: A long-term NEI/Foundation Fighting Blindness-supported clinical trial in RP patients broadly (not USH4-specific) showed vitamin A may modestly slow RP progression, though it does not halt or cure it. Applicability to ARSG-specific RP has not been separately studied.
• No ARSG-targeted small-molecule or enzyme-replacement therapy currently exists (unlike some other lysosomal disorders), though the lysosomal storage mechanism (heparan sulfate accumulation) is conceptually analogous to diseases where enzyme replacement or substrate reduction therapy has been explored (e.g., MPS disorders) — this remains speculative for USH4 and not clinically established.
• NCIT term: NCIT:C15986 (Pharmacotherapy) as the generic treatment_term for vitamin A supplementation, with therapeutic_agent bound to retinol/vitamin A (CHEBI).

Advanced/Experimental Therapeutics

• Gene therapy: Broadly under investigation for Usher syndrome (multiple USH1/USH2 gene-specific programs, e.g., AAV-based approaches, antisense oligonucleotide exon-skipping for USH2A), but no ARSG-specific gene therapy program has been identified in the literature/trial registries reviewed. Given ARSG's relatively large coding sequence and the loss-of-function mechanism, AAV-based gene augmentation (as pursued for other recessive LOF retinal disease genes) would be a plausible future therapeutic direction but is not yet in development based on available sources. NCIT:C15238 (Gene Therapy).
• RNA-based therapies: Antisense oligonucleotide and RNA-editing approaches are in development for other Usher genes (particularly USH2A); not reported for ARSG.
• No cell-based or CRISPR gene-editing therapies specific to USH4 were identified.

Hearing Management

• Hearing aids: First-line for the moderate-to-severe SNHL of USH4, given the later onset and progressive (rather than profound congenital) nature of the hearing loss — contrasting with USH1, where cochlear implantation is often needed early due to profound congenital deafness.
• Cochlear implantation: A reasonable option later in the disease course if hearing aids become insufficient, as used in USH2/USH3.
• Assistive listening devices, speech therapy as needed.
• NCIT term: no dedicated device term for hearing aids in NCIT; cochlear implantation may map to a device/procedure NCIT term where applicable.

Vision Support

• Low-vision rehabilitation services, orientation and mobility training, optical/electronic low-vision aids — NCIT:C15315 (Rehabilitation).
• Genetic counseling for patients and at-risk relatives given autosomal recessive inheritance — NCIT:C15240 (Genetic Counseling).

Treatment Outcomes

No systematic treatment-response, adverse-event, or comparative-effectiveness data specific to USH4 patients were identified — reflecting both the rarity of the condition and the absence of disease-specific interventional trials.

Treatment Strategy

Management is currently symptomatic and multidisciplinary (ophthalmology, audiology, genetics, low-vision/hearing rehabilitation services), following general Usher syndrome clinical practice guidelines rather than an USH4-specific treatment algorithm. No combination or genotype-guided precision therapy currently exists for this gene.

13. Prevention

Prevention Levels

• Primary prevention: Not applicable in the traditional sense (no modifiable risk-factor avoidance can prevent a monogenic recessive disorder); the relevant "primary prevention" tool is reproductive genetic counseling and carrier screening in at-risk families/populations (e.g., relatives of Yemenite Jewish or Portuguese founder-variant carriers), including preimplantation genetic diagnosis (PGD) or prenatal testing for at-risk couples.
• Secondary prevention: Early molecular diagnosis (via genetic testing in patients presenting with combined late-onset RP + hearing loss, even without classic vestibular Usher features) allows earlier initiation of low-vision and hearing rehabilitation before profound impairment develops.
• Tertiary prevention: Standard RP/hearing-loss complication management (as above) to preserve function and quality of life once disease is established.

Immunization

Not applicable — USH4 has no infectious etiology.

Screening and Early Detection

• No population-based newborn screening program exists (or would be expected, given the late-onset nature).
• Carrier screening / genetic counseling is the most relevant preventive tool, particularly in populations with known founder alleles (Yemenite Jewish community for p.Asp45Tyr).
• Cascade genetic testing of at-risk siblings/relatives of an index USH4 patient is appropriate given autosomal recessive inheritance and the substantial reproductive-planning implications.

Behavioral Interventions

No specific behavioral/lifestyle interventions have been shown to prevent or delay ARSG-related disease onset.

Public Health / Environmental Interventions

Not applicable — no environmental exposure has been implicated in causation.

Prophylaxis

No prophylactic medications or procedures are established for at-risk (biallelic, presymptomatic) individuals.

14. Other Species / Natural Disease

Mouse (Mus musculus, NCBITaxon:10090)

• Arsg knockout (Arsg−/−) mice recapitulate key features of the human retinal phenotype: progressive photoreceptor degeneration beginning between 1–6 months of age, with >50% photoreceptor loss by 24 months, accompanied by reactive astrogliosis, outer-retina-predominant microgliosis, and elevated lysosomal protein expression (Kruszewski et al. 2016, IOVS, PMID:26975023). This model strongly supports RPE-lysosomal-storage as the retinal disease mechanism (see Section 6) and represents a high-fidelity model for the retinal component of USH4, though the paper does not report on auditory phenotyping of this line in the sources reviewed here.
• Orthologous gene: Mouse Arsg (MGI ortholog of human ARSG).

Dog (Canis lupus familiaris, NCBITaxon:9615)

• American Staffordshire Terriers (and related American Pit Bull Terriers) carry a naturally occurring ARSG missense variant (c.296G>A, p.Arg99His) causing a late-onset, adult-onset neuronal ceroid lipofuscinosis (NCL)-like neurodegenerative disorder with progressive ataxia and thalamocerebellar neuronal storage of ceroid lipopigment, typically presenting between 3–6 years of age (Abitbol et al. 2010, PNAS, PMID:20679209).
• Notably, the identical p.(Arg99His) variant has since been reported in a human USH4 patient (homozygous in one subject, heterozygous in another, in the Bauwens et al. 2025 cohort), who presented with the isolated USH ocular/auditory phenotype without the broader neurological (ataxic/cerebellar) manifestations seen in the canine disease — an important cross-species phenotype divergence worth flagging as a HUMAN_MODEL_MISMATCH-type consideration: the same variant produces a primarily CNS/neurodegenerative storage disease in dogs but an apparently CNS-sparing, sensory-restricted (retina + cochlea) phenotype in the one human case reported to carry it.
• A more recent study additionally examined retinal function deficits in American Staffordshire Terriers with this late-onset ARSG-associated neurodegenerative disease, providing further cross-species retinal phenotyping data (2024–2025 publication; PubMed ID referenced as 41295716 in search results — confirm directly before citing, as this ID was not independently verified via full-text retrieval in this session).
• Veterinary relevance: ARSG-NCL is used as a breed-health genetic test in American Staffordshire Terriers (commercial panels available), demonstrating direct veterinary clinical importance beyond its comparative-biology value.

Comparative Biology

The dog and mouse models together support a conserved role for ARSG in lysosomal heparan sulfate catabolism across mammals, with tissue-specific consequences of loss of function (retina/RPE-restricted degeneration in mouse and the isolated human USH4 case vs. broader CNS/thalamocerebellar storage disease in the canine NCL phenotype) — suggesting that the precise clinical presentation of ARSG deficiency may depend on additional genetic background, allele-specific residual activity, and/or species-specific tissue distribution of ARSG expression and heparan sulfate substrate turnover requirements.

Transmission

Not applicable — ARSG deficiency is a genetic, non-infectious, non-zoonotic condition; there is no cross-species transmission risk (the human and canine diseases are independently occurring genetic disorders of the orthologous gene, not a transmissible disease).

15. Model Organisms

Model Limitations

• Neither model has been reported (in the sources reviewed) to comprehensively recapitulate the auditory (cochlear) component of human USH4 — the mouse study focused on retinal histopathology, and the canine model's primary described phenotype is CNS/cerebellar rather than cochlear. This represents a notable gap: the cochlear/auditory cell-autonomous mechanism of ARSG deficiency remains largely uncharacterized at the animal-model level based on available literature.
• No iPSC-derived, organoid, or other non-animal (NAM) model system for ARSG deficiency (e.g., retinal organoid or inner-ear organoid) was identified in this search — representing an opportunity for future human-cell model development.
• No CRISPR knockout/knock-in cell-line screens or DepMap-type functional genomics data specific to ARSG were identified.

Research Applications

The mouse Arsg−/− model is well-suited for studying the RPE-lysosomal-storage mechanism of retinal degeneration and could support preclinical testing of substrate-reduction or enzyme-replacement strategies; the canine model offers a naturally occurring, genetically homogeneous (breed-associated) system for studying ARSG-related neuronal storage pathology and could be valuable for comparative therapeutic (e.g., gene therapy) proof-of-concept studies given the tractability of companion-animal clinical trials.

Summary of Key Ontology Term Suggestions

Key Evidence Gaps and Caveats for Curation

1. Small evidence base: Only 31 published patients worldwide — every clinical parameter (onset ages, progression rates, penetrance) carries wide confidence intervals and should be curated with appropriate FrequencyEnum caution rather than presented as fixed values.
2. Discrepant hearing-loss onset estimates between the 2022 (calculated ~age 17) and 2024/2025 (typical 40–58 years) cohorts — flag as an open question rather than reconciling artificially.
3. Cross-species model mismatch: the canine ARSG p.R99H variant causes a CNS/cerebellar-predominant NCL phenotype, while the same variant in the one reported human carrier causes an isolated sensory (USH4) phenotype without neurological involvement — a genuine HUMAN_MODEL_MISMATCH worth flagging explicitly.
4. No auditory-specific animal model has been reported; the mechanistic chain for cochlear pathology is inferred by analogy to the retinal mechanism, not directly demonstrated.
5. Several ORPHA/ClinVar/gnomAD-specific data points (exact ORPHA code, precise allele frequencies) could not be independently confirmed via full-text retrieval in this session (OMIM and PubMed pages returned access-restricted/cookie-blocked responses) and should be verified directly against OMIM #618144, ClinVar, and gnomAD before final curation.

Sources

• OMIM #618144 — Usher Syndrome, Type IV; USH4
• OMIM *610008 — Arylsulfatase G; ARSG
• Khateb et al. 2018, "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans" — PMID:29300381
• Abad-Morales et al. 2020, "Identification of a novel homozygous ARSG mutation as the second cause of Usher syndrome type 4" — PMID:32455177
• Peter et al. 2022, "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants" — PMID:35226187
• Bauwens et al. 2025, "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants" — PMID:39199020, Clinical Genetics
• Kruszewski et al. 2016, "Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice" — PMID:26975023, IOVS
• Abitbol et al. 2010, "A canine Arylsulfatase G (ARSG) mutation leading to a sulfatase deficiency is associated with neuronal ceroid lipofuscinosis" — PMID:20679209, PNAS
• Delmaghani & El-Amraoui 2022, "The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms to a new classification" — PMID:35353227, Human Genetics
• GeneCards — ARSG gene
• PanelApp Genomics England — ARSG (Monogenic hearing loss)
• Hearing Health Foundation — Usher Syndrome Treatments

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.